Top Markets
#1 Pleasing Gold Pleasing Gold +1,548.36%
#2 PulseChain PulseChain +58.48%
#3 Merlin's Seal BTC Merlin's Seal BTC +32.56%
#4 Ontology Gas Ontology Gas +32.42%
#5 BOOK OF MEME BOOK OF MEME +30.49%
#6 Pump.fun Pump.fun +24.97%
#7 Unit Pump Unit Pump +24.97%
#8 Nockchain Nockchain +21.96%
#9 RSK Infrastructure Framework RSK Infrastructure Framework +21.19%
#10 Neiro Neiro +19.16%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rangering i aksjer #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Aksjekurs
$0.12164306
Sist synkronisert: 2024-11-11
Markedsverdi
$38.53M
Endring (1 dag)
-4.14%
Endring (1 år)
0.00%
Land
AU
Handel PharmAust Limited (PAA)

Kategori

Healthcare
P/B-forhold for PharmAust Limited (PAA)
P/B-forhold per August 2026 TTM: 8.34
Ifølge PharmAust Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 8.34. Ved slutten av 2024 hadde selskapet et P/B-forhold på 7.07.
P/B-historikk for PharmAust Limited fra 2001 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) 8.34 -66.96%
2025 25.24 257.09%
2024 7.07 14.20%
2023 6.19 118.92%
2022 2.83 -12.60%
2021 3.24 -39.88%
2020 5.38 357.35%
2019 1.18 54.04%
2018 0.76 -23.38%
2017 1.00 -25.35%
2016 1.34 27.23%
2015 1.05 -36.35%
2014 1.65 -90.55%
2013 17.45 671.52%
2012 2.26 -68.36%
2011 7.15 99.09%
2010 3.59 333.85%
2009 0.83 5.81%
2008 0.78 -13.33%
2007 0.90 -33.57%
2006 1.36 -44.16%
2005 2.43 -64.38%
2004 6.83 667.26%
2003 0.89 -50.23%
2002 1.79 19.65%
2001 1.49 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -23.94%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -25.15%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -69.95%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -55.52%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH